HARROW, INC. (HROW)
HARROW, INC. (HROW) from its SEC filings: 2025 revenue $272.3 million (+36% vs the year before), net margin -2%, free cash flow $43.0 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $272.3 million |
| Revenue growth | +36% |
| Net income | -$5.1 million |
| Net margin | -1.9% |
| Free cash flow | $43.0 million |
| Diluted EPS | $-0.14 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +11% |
| Cash | $83.9 million |
| Long-term debt | $300.0 million |
| Share count, 1 year | +1% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.